Interleukin-15 (IL-15) is a pro-inflammatory cytokine that is required for the survival and activation of memory CD8
INTRODUCTION
Interleukin-15 (IL-15) plays a multifaceted role in innate and adaptive immunity by regulating the development, homeostasis and functions of hematopoietic and non-hematopoietic cells. 1, 2 Even though IL-15 mRNA can be detected in different organs such as placenta, skeletal muscle, intestine and kidney under steady state, 3 the protein expression is below the level of detection by conventional methods and is limited to macrophages and dendritic cells (DCs). 4 IL-15 protein can be expressed with either a short or a long signal peptide (SSP and LSP, respectively). Whereas the SSP-IL-15 is not released from cells, the LSP-IL-15 is inefficiently secreted. 5 The IL-15 receptor (IL-15R) complex consists of the ligandbinding IL-15Ra chain (CD215), the b chain (CD122; also used by IL-2) and the common gamma (c c ) chain. 2 The biological activities of IL-15 are mostly mediated by the IL-15:IL-15Ra complex, produced by non-T cells and 'trans-presented' to responder cells that express the IL-2/15Rbc c complex. 6 This peculiar and almost unique requirement for trans-presentation by IL-15Ra suggests that the biological effects of IL-15 are tightly regulated not only at the level of IL-15 production but also by the constraints imposed by trans-presentation. Tissuespecific ablation of IL-15Ra has revealed distinct patterns of requirement for the source of the trans-presented IL-15. For example, natural killer (NK) cells require IL-15 to be trans-presented by both DCs and macrophages while central memory CD8
1 T cells require DC-derived IL-15. 7, 8 Moreover, cell-bound IL-15 can act in cis on producer cells 9 and the IL-15: IL-15Ra complex can be released by proteolytic cleavage, 10 indicating further complexity in IL-15 signalling.
While studies using mice deficient for either IL-15 or IL15Ra have clearly established that both are required for the development and homeostasis of NK cells and CD8
1 T cells, deciphering the role of IL-15Ra in immune responses remains a challenging issue due to the complexities of IL-15 signalling outlined above. 11 IL-15 plays an important role in anti-viral immune responses, both in activating the innate immune system and in generating effective memory.
12-14 IL-15 also contributes to the pathogenesis of several autoimmune diseases including inflammatory bowel disease, rheumatoid arthritis and psoriasis. 15 Recently, we and others have shown that IL-15 plays a crucial role in the pathogenesis of autoimmune type 1 diabetes (T1D). 16, 17 In this study, we investigated whether IL-15 trans-presentation plays an essential role in T1D pathogenesis. We show that IL-15Ra deficiency does not affect T1D incidence in two different mouse models and that IL-15Ra is also dispensable for antigen cross-presentation to CD8
1 T cells, and key process in activating autoreactive CD8 1 T cells.
MATERIALS AND METHODS
Mouse strains NOD.Il15 -/-and NOD.scid.Il15 -/-mice have been previously described.
16 Il15ra -/-mice obtained from the Jackson laboratory were backcrossed to C57Bl/6 and non-obese diabetic (NOD) mice for 6 and 11 generations, respectively. NOD.scid mice were obtained from the Jackson laboratory and crossed with Il15ra -/-mice to generate NOD.scid.Il15ra -/-mice. Rat insulin promoter-glycoprotein (RIP-GP) transgenic mouse expressing the envelope GP antigen of lymphocytic choriomeningitis virus (LCMV) in pancreatic islets 18, 19 were crossed with Il15 -/-and Il15ra -/-mice to generate RIP-GP.Il15 -/-and RIP-GP.Il15ra
-/-mice. RIP-GP.Rag1 -/-mice were generated in our animal facility. 20 OT-1 TCR transgenic mice were obtained from Jackson laboratories and were crossed with C57Bl/6. Il15ra -/-mice to generate OT-1.Il15ra -/-mice. Mice were housed in micro-isolated sterile cages under specific pathogen-free conditions. All experimental protocols on mice were approved by Université de Sherbrooke Ethics Committee for Animal Care and Use in accordance with guidelines established by the Canadian Council on Animal Care.
LCMV and Listeria strains
LCMVArmstrong strain and Listeria monocytogenes expressing ovalbumin protein (LM-OVA) were kind gifts from Drs P. Ohashi (University of Toronto) and C. Krawczyk (McGill University), respectively. LCMV stock was prepared through a single passage in BHK21 cells. LM-OVA was grown in brain-heart infusion medium for 15 h at 37uC.
LCMV infections and adoptive transfer
Eight-week-old RIP-GP, RIP-GP.Il15
-/-and RIP-GP.Il15ra -/-mice were infected with 2 3 10 4 plaque forming units (pfu) of LCMV intravenously and monitored for T1D and insulitis. Splenocytes were isolated 14 days after infection of WT, Il15 -/-and Il15ra -/-mice and 1 3 10 7 cells were adoptively transferred to RIP-GP.
Rag1
-/-mice. The recipients were followed for T1D and insulitis.
Monitoring T1D and evaluation of insulitis Spontaneous T1D development in NOD and NON.Il15ra
-/-mice were monitored for up to 40 weeks, using DIASTIX strips (Bayer, Leverkusen, Germany) to test the glucose in the urine. Mice were monitored three times a week. Mice were considered diabetic when three consecutive readings over a week were positive (.28 mM in the urine). As the progression of T1D is rapid in the RIP-GP model of T1D, blood glucose levels were monitored every 2 days from day 7 after LCMV infection, and 5 days after adoptive transfer. T1D incidence was monitored in the blood using Accu-Check strips (Roche Diagnostics, Missisauga Canada). Animals that showed more than 15 mM of blood glucose on two consecutive readings were considered diabetic and were euthanized. Insulitis was scored as previously described. 16 Briefly, at killing, pancreases were fixed in buffered formalin and embedded in paraffin. Three non-overlapping (200 mm apart), 5-mm sections were stained with hematoxylin and eosin and blindly scored for insulitis.
Viral clearance
Viral titer was evaluated on day 14 following LCMV infection. The liver tissue was homogenized in phosphate-buffered saline using a bead mill MM 400 (Retsch, Hann, Germany). Serial 10-fold dilution of the homogenate was tested on the fibrosarcoma cell line MC57G to calculate the plaque formation units, following published methods. 21 In vivo cross-presentation assay Mice of the indicated genotypes were infected with 5 3 10 3 colony forming units (CFU) of Listeria monocytogenes expressing ovalbumin protein (LM-OVA) intravenously on day 0. The following day 10 7 5-(6)carboxyfluorescein diacetate succinimidyl ester (CFSE) labelled CFSE-labelled splenocytes from OT1 or OT-1.Il15ra
-/-mice were injected intravenously. 22 Six days later, proliferation of CFSE-labelled OT-1 cells in the spleen was assessed by flow cytometry.
Statistical analysis
Cumulative incidence of T1D was analysed using the Prism software (GraphPad, California, USA). For diabetes incidence, statistical significance was calculated using log-rank (MantelCox) test.
RESULTS AND DISCUSSION
IL-15Ra is dispensable for spontaneous T1D in NOD mice, but shows variable requirement for the maintenance of autoreactive CD8
1 T cells We have shown previously that IL-15 plays a critical role in activating diabetogenic CD8
1 T cells in the NOD mouse model. 16 To determine whether trans-presentation of IL-15 is essential to activate pathogenic CD8 1 T cells in T1D, we generated NOD.Il15ra
-/-mice and followed them for T1D development. We observed that the cumulative incidence of T1D in female NOD.Il15ra -/-mice was comparable to that of control NOD mice (Figure 1a ), suggesting that IL-15Ra is dispensable for IL-15-dependent pathogenic mechanisms in T1D.
It has been demonstrated that the lack of either IL-15 or IL15Ra causes a decrease in the frequency of memory CD8
1 T cells, 1, 23 and that IL-15 is required mainly for the maintenance of antigen-experienced memory CD8
1 T cells and not for their generation. 12, 24 We have shown previously that CD8 1 T cells from diabetic 8.3-NOD mice expressing a highly pathogenic transgenic TCR on CD8
1 T cells caused T1D following adoptive transfer -/-recipients, 16 surprisingly NOD.scid.Il15ra
-/-recipients developed T1D with frequency and kinetics similar to that of control NOD.scid recipients (Figure 1c and e, middle panel). These results indicated that, contrary to the results obtained with 8.3 T cells, isletspecific effector T cells present in a polyclonal repertoire can be sustained even in the absence of trans-presented IL-15Ra.
It has been shown that the excess of soluble IL-15 promotes the activation of NK and memory CD8
1 subsets in mice and humans. 6, 25, 26 Therefore, it is possible that IL-15 presents in the circulation of NOD.scid.Il15ra
-/-recipients can bind to IL-15Ra present on donor cells and trans-present IL-15 to autoreactive effector CD8 1 T cells. To address the role of donor-derived IL15Ra, we adoptively transferred splenocytes from diabetic NOD.
Il15ra
-/-mice to NOD.scid.Il15ra -/-recipients (Figure 1d and e). T1D was not observed in the NOD.scid.Il15ra
-/-recipients of splenocytes from diabetic NOD.Il15ra
-/-mice, presumably due to the inability of the donor effector cells to be maintained in the absence of IL-15Ra of either recipient or donor origin (Figure 1d ). These mice showed minimal evidence for insulitis (Figure 1e , bottom panel). However, the inability of antigen-experienced 8.3 TCR transgenic CD8
1 T cells to maintain their pathogenicity in NOD.scid.Il15ra
-/-recipients despite the availability of IL-15Ra on donor cells (Figure 1b) begs additional explanation. It is possible that some of the autoreactive TCRs in the polyclonal repertoire may have overcome the dependency on IL-15Ra due to higher affinity of their TCR toward their cognate autoantigens and/or help from donor CD4
1 T cells present in the polyclonal repertoire. 27 Nevertheless, the above results indicate that (i) IL-15 trans-presentation is dispensable for the initial pathogenic activation of diabetogenic T cells, (ii) its requirement for sustaining the pathogenic potential of antigen-experienced CD8
1 T cells may vary depending on the clonal diversity of the autoreactive T cells, and (iii) when required for the latter, IL-15Ra expressed on antigen-experienced CD8
1 T cells likely promotes their homeostatic expansion and/or pathogenic functions.
IL-15Ra is not needed for virus-induced T1D in the RIP-GP model and for clearing LCMV To further study the role of IL-15Ra in the autoimmune disease process, we used the LCMV-induced model of T1D in the C57Bl/6 genetic background. RIP-GP mice express the LCMV GP under the control of the rat insulin promoter. T cells specific to the GP antigen in the naive repertoire are ignorant of the transgenic viral protein expressed in pancreatic islets. 18 Following LCMV infection, activated GP-specific cells recognize and destroy the islets resulting in T1D.
18,28 RIP-GP transgenic control, Il15 -/-and Il15ra -/-mice were infected intravenously with 2 3 10 4 pfu of LCMV and were followed for T1D development. Even though T1D onset was delayed by 4-5 days in RIP-GP.Il15ra
-/-mice when compared to control RIP-GP mice, 9 out of 10 mice developed T1D (Figure 2a) .
RIP-GP.Il15
-/-mice showed a similarly delayed disease onset; however, only 50% of them developed T1D even after 35 days. Consistent with the delayed disease kinetics RIP-GP.Il15ra
-/-mice and RIP-GP.Il15
-/-mice that developed T1D showed less severe degree of insulitis, while control mice showed severe islet damage (Figure 2b) . RIP-GP.Il15
-/-mice that did not develop T1D harboured islets that were mostly normal. Intriguingly, none of Il15 -/-RIP-GP mice had cleared the viral load at killing, A previous study has reported efficient clearance of LCMV in the absence of IL-15 or IL-15Ra 13 The differences between the results presented here and the above study may result from the route of infection and the time from infection to the analysis of the viral load. Furthermore, viral clearance following systemic, but not mucosal route of infection with influenza virus has been shown to be dependent on IL-15.
29

IL-15Ra is required to maintain effector CD8
1 T cells generated following viral infection The requirement for IL-15 during recall responses appears to vary depending on the pathogen involved as well as the route of infection. 30, 31 While IL-15 was shown to be necessary for memory generation following acute intravenous infections, 12 memory T cells generated following the entry of pathogens via mucosal surfaces were not dependent on IL-15.
14, 29 To assess whether antigen-specific T cells that were generated in the absence of IL-15 trans-presentation retain their pathogenic potential, splenocytes from LCMV-infected control C57BL/6, Il15 -/-and Il15ra -/-mice were adoptively transferred to RIP-GP.Rag1
-/-recipients. While splenocytes from LCMV-infected control mice induced T1D in RIP-GP.Rag1
-/-recipients, cells from Il15ra -/-mice failed to induce disease (Figure 3a) , indicating that antigen-experienced LCMV-GP-specific CD8 1 T cells need IL-15Ra to sustain pathogenic potential.
In an early study before the discovery of IL-15 transpresentation, Schluns et al. reported using both Il15 -/-and Il15ra -/-mice that IL-15Ra but not IL-15 is dispensable for activating CD8
1 T cells following vesicular stomatitis virus infection. 12 This study concluded that primary antiviral response may not require IL-15 due to low expression of IL-15ra on naive CD8
1 T cells, whereas activated cells expressing higher levels of IL-15Ra are dependent on it to generate memory cells and their maintenance. The inability of diabetogenic CD8
1 T cells from LCMV-infected Il15ra -/-mice to induce disease in RIP-GP.
Rag1
-/-recipients (Figure 3a) is consistent with the requirement of IL-15Ra to maintain virus-induced memory CD8 1 T cells. However, it stands in sharp contrast to the ability of splenocytes from diabetic NOD.Il15ra
-/-mice to transfer disease to NOD.scid recipients (Figure 1d) . The possibility that IL-15Ra expressed by recipient cells might have complemented its absence on donor CD8
1 T cells in the NOD model is untenable because this was not the case in RIP-GP model (Figure 3a and d) . The possibility of differential CD4 help from within the donor cell population is also not plausible because both donors harboured a polyclonal repertoire. Several factors could contribute in a complex way to the differential requirement for IL-15Ra to sustain the pathogenic potential of T cells in these two T1D models. First, diabetogenic T cells in the NOD model are directed against multiple autoantigens, whereas the target of pathogenic T cells in the RIP-GP model is limited to one epitope, which would limit the severity of the pathogenic process in the latter case. Second, unlike in the case of LCMV infection, where the antigen is eliminated after viral clearance, the autoantigens in the NOD islets are continuously available until the islets are completely destroyed. This implies that the donor cells from diabetic NOD.Il15ra
-/-mice may contain a pool of polyclonal autoreactive T cells that are still in early stages of activation, whereas GP-reactive cells from LCMV-infected have already differentiated into effector and memory lineages, thus requiring IL-15Ra to sustain their pathogenicity. Third, the pro-diabetic genetic background might diminish the requirement for IL-15 trans-presentation in maintaining the pathogenic potential of autoreactive T cells.
In contrast to cells from LCMV-infected Il15ra -/-donors, splenocytes from Il15 -/-mice efficiently transferred T1D to RIP-GP.
-/-recipients that were comparable to control cells (Figure  3a-b) . This could be explained by the presence of uncleared LCMV from Il15 -/-donors. This notion is supported by rapid induction of T1D in RIP-GP.Rag1
-/-mice by adoptive transfer of splenocytes from uninfected mice along with LCMV ( Figure 3 ).
IL-15 but not IL-15ra is required for antigen crosspresentation to CD8
1 T cells in vivo T1D onset in the NOD mouse coincides with shedding of islet autoantigens during physiological tissue remodelling that is taken up by DCs and cross-presented to autoreactive CD8
1 T cells in pancreatic draining lymph nodes. 32, 33 Similarly, initiation of the immune response following LCMV or Listeria monocytogenes infections is mediated by the cross-presentation of pathogenderived antigens to CD8 1 T cells. 22 IL-15 has been implicated in antigen presenting functions of DCs. 9 To examine the role of IL-15 trans-presentation in antigen cross-presentation to CD8 35 we postulated that cross-presentation of systemically administered LM-OVA might be defective in the absence of IL-15 trans-presentation. However, our results from the NOD model and the RIP-GP model suggested that IL-15 transpresentation is not required to activate diabetogenic T cells. To directly test the requirement of IL-15Ra in antigen crosspresentation 5 3 10 3 CFU of LM-OVA was administered intravenously to wild-type C57Bl/6, Il15 -/-and Il15ra -/-mice followed by injection of 10 7 CFSE-labelled splenocytes from OT-1 TCR transgenic mice. As expected, OT-1 cells showed robust proliferation in LM-OVA-infected WT mice (Figure 4a ). While the injected OT-1 cells failed to proliferate in Il15 -/-mice, the same cells underwent efficient proliferation in Il15ra -/-recipients to the level comparable to that observed in control mice. Proliferation of OT-1 cells in Il15ra -/-hosts was not due to complementation by IL-15Ra expressed on donor OT-1 cells as shown by robust proliferation of Il15ra -/-OT-1 cells in Il15ra -/-hosts (Figure 4b ). These results show that while IL-15 is essential to mediate antigen cross-presentation to CD8
1 T cells, this process does not depend on trans-presentation of IL-15 by IL-15Ra.
CONCLUSIONS
While it is well known that IL-15Ra is critical for mediating certain functions of IL-15 such as development and maintenance of NK cell and memory CD8 1 T lymphocytes, our findings show that IL-15 can mediate at least some of its key functions without the need for trans-presentation. We have shown that induction of autoimmune diabetes in two different animal models and viral clearance, which are dependent on IL-15, do not require its trans-presentation by the IL-15Ra chain. We have also shown that antigen cross-presentation to CD8
1 T cells, a key process that underlies pathogenesis of T1D and plays an important role in immune response against intracellular pathogens, does not require IL-15Ra.
Our findings highlight the intricacies of IL-15 signalling that should be considered in therapeutic targeting of the IL-15 signalling pathway. An early study has shown that simian IL-15 can signal via the human IL-15ac in COS7 cells. 36 Our data indicate that IL-15Ra -independent signalling can occur in vivo. During the initiation of the immune response, either in spontaneous T1D or in the clearance of LCMV, IL-15 may primarily act on the non-lymphoid cells to initiate the immune responses. Consistent with this prediction, we have shown that the inhibition of IL-15 signalling using anti-CD122 mAb Tmb1 targeting IL-15Ra during a short-time window prior to disease onset attenuated disease development in the NOD mouse. 16 It is also possible that IL-15 may utilize a receptor protein other than IL-15Ra to engage the IL-15ac complex on antigen-presenting cells as shown in mast cells. 37 Characterization of the IL-15 signalling machinery in non-lymphocytes, particularly antigen-presenting cells, will contribute to a better understanding of the IL-15 signalling and could lead to new approaches for its therapeutic targeting in autoimmune diseases. 
